Posts in category All News
Screener.in: The destination for Intelligent Screening & Reporting in India (29-06-2024)
Hi @kowshick_kk and Screener team, just posting here for visibility as I have already shared with the team but I’m hoping this can be implemented on priority.
Need additional data for ‘3 quarters back’. (corresponding previous quarter of upcoming quarter)
Currently - Sales, Operating Profit & Net Profit are available.
Here are the parameters needed:
- Other income 3 quarters back
- Extraordinary Income 3 quarters back
- Profit before Tax 3 quarters back
I need it for the upcoming earnings season so that data can be compared Year on Year.
The same data is available for the ‘preceding year quarter’ like this:
I have been requesting this since a couple of quarters now and while I do understand it is more data you have to show, but it is data that is already available and just needs to be accessible to users.
Hoping for a quick resolution!
Tata Steel – Would be merger be of any value? (29-06-2024)
This information is little off topic however, just wanted to share my understanding and things that is happening with TATA Steel.
After Tata Steel UK initiated legal action against an employee’s union after their announcement on early shutdown of its operations at the Port Talbot facility. This all started when Tata steel planned to shut down its loss-making business by decommissioning two blast furnaces and replace it with Electric Arc furnace project. The Company had also sought support from the UK Government and came to an agreement to invest £500 million.
Now what’s the issue?
Around 2800 jobs will be lost in closure of the blast furnaces. Also, the long-term Steel making sustainability would come to a pause.
Hence, Employee union’s secretary Sharon Graham stated that “We call on the real decision makers in Mumbai to take hold of this dispute, sit down, negotiate, and realise that the investment secured will be good for the company and workers.”
What the Company is doing?
The Company has urged the Union to withdraw its strike that is going to start from July 8, 2024 and consider its proposal which includes “generous” employee support packages, training, and skills development.
In the coming days, if the Company is unable to continue to safely and stably operate the assets through the period of strike action, they will have to pause or stop heavy-end operations (including both blast furnaces) on the Port Talbot site.
The Company has emphasized that shutting down operations would be extremely costly and disruptive throughout the supply chain.
They also stated that safety of people on the site will be their priority.
To Conclude, Tata Steel being one of the largest steel manufacturing Company around the globe, these disruptions would not hamper the long-term goals of the Company. However, if the operations are being paused or stopped for a longer duration it would badly affect the company’s topline growth in the near term.
Do share your thoughts on above information.
Poll results moral defeat for Modi but he is continuing as if nothing changed: Sonia Gandhi (29-06-2024)
Vraj Iron and Steel IPO ends with strong subscription (29-06-2024)
Vraj Iron and Steel IPO ends with strong subscription (29-06-2024)
Multi-Disciplinary Reading – Book Reviews (29-06-2024)
But these funds performance avialable since 2007 only post 2008 crisis Central banks printed so much monies which expaned PE ratio to unsustainable level for QUALITY companies
Wockhardt: an NiCE story (29-06-2024)
Excerpt from Chairman’s Speech at AGM, convened on June 28, 2024, at 11 am
- Over a span of 25 years, we dedicated substantial efforts to establish a global antibiotic research organisation.
- Fostered a culture of Research and Innovation, collaborating with more than 30 global organisations.
- Invested over US$ 500 million in discovering antibiotics to address unmet medical needs.
- Our diverse antibiotic portfolio tackles antimicrobial resistance across various classes, developed over 30-40 years, targeting infections in both hospital and community settings.
EMROK & EMROK O
- EMROK & EMROK O have treated more than 65,000 patients.
- Successfully concluded 4 new clinical studies covering bloodstream infections, bone and joint infections, community-acquired bacterial pneumonia, and infections in immunosuppressed patients.
- Completed New Drug Application (NDA) submissions in 10 Emerging Markets countries and aiming for 5-6 additional countries by Q2 of FY 2025.
- Anticipating substantial growth in the current year due to these expansions.
WCK 4873 (Nafithromycin), trademarked as MIQNAF
- MIQNAF (WCK 4873) offers an ultrashort, 3-day oral treatment for community-acquired bacterial pneumonia, achieving a 97% success rate.
- Current treatments face up to 60% resistance.
- Filed New Drug Application (NDA) with the Drug Controller General of India (DGCI) and anticipate commercial launch in India by the second half of FY25.
- Planning NDA filings in selected Emerging Markets and foreseeing strong sales in FY26.
WCK 5222 (Zidebactam/Cefepime), trademarked as ZAYNICH
- A groundbreaking new antibiotic developed by Wockhardt.
- This proprietary drug, designed to combat major superbugs, is the first of its kind discovered in the past 50 years.
- Currently in Global Phase 3 clinical trials.
- ZAYNICH was granted compassionate use approval by the DCGI for 30 critically ill patients unresponsive to existing antibiotics.
- Achieving a 100% success rate, ZAYNICH saved the lives of all recipients, with notable cases published in prestigious international journals.
- To date, ZAYNICH has saved over 30 lives, with DCGI approval secured for a small-scale clinical trial involving carbapenem-resistant patients in India.
- Pending completion by FY25, approval would enable ZAYNICH to become available in India, marking a significant milestone in its clinical deployment.
- The US FDA granted ‘Expanded Access IND’ approval for WCK 5222 (ZAYNICH) to treat a young cancer patient at the University of California Irvine School of Medicine, Orange County.
- Despite nine months of unresponsiveness to current US antibiotics, the patient showed significant improvement within four weeks of ZAYNICH administration.
- The treatment resulted in complete healing of large wounds and eradication of infections, allowing the patient to resume chemotherapy for ongoing cancer treatment.
- CLSI, a globally-recognized US body, has approved a susceptibility breakpoint of 64 mg/L for ZAYNICH.
- This breakpoint applies to a wide spectrum of Gram-negative pathogens resistant to multiple drugs.
- ZAYNICH demonstrates unprecedented effectiveness with its high bacteria kill power, crucial for extreme multi-drug resistant organisms.
- For the first time, a breakpoint of 64 mg/L covers the entire spectrum of 10-resistant Gram-negative pathogens, underscoring ZAYNICH’s clinical potency.
- Clinical trials under compassionate use show a 100% success rate in critically ill patients, affirming its safety and efficacy over 70 days.
- ZAYNICH’s achievement of the investigational breakpoint at a CLSI plenary session on June 24, 2024, marks a historic milestone, a source of pride for Wockhardt and India.
- Global Phase III clinical trials for ZAYNICH are anticipated to conclude by FY25.
- Plans include filing for regulatory approvals in the US, Europe, and other regions following trial completion.
- Global approval for ZAYNICH’s launch worldwide is expected in FY26.
- Strategically, we aim to maximize market value through a dual strategy: direct marketing in India and Emerging Markets, alongside licensing agreements with global pharmaceutical companies for US, Europe, and other developed regions.
Source: https://www.wockhardt.com/wp-content/uploads/2024/06/chairmans-agm-speech-2024.pdf